Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug - Biotech, Pharma and Life Science Channel
Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets, that promote clotting.
Analysts believe that peak sales of Brilinta could reach $2bn or more, but Brilinta will face stiff competition in the blood-thinning market, notably from Plavix.
What is BRILINTA?
BRILINTA is a type of prescription antiplatelet medication for people who have had a recent heart attack or severe chest pain that happened because their heart wasn't getting enough oxygen and who are being treated with medicines or procedures to open blocked arteries in the heart. BRILINTA is used with aspirin to stop platelets from sticking together and forming a blood clot that could block blood flow to the heart and cause another, possibly fatal, heart attack. Platelets are small cells in the blood that help with normal blood clotting.
Why BRILINTA?
BRILINTA used with aspirin lowers your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. These can be fatal. In fact, in a large clinical study BRILINTA was even better than Plavix® (clopidogrel bisulfate) tablets at lowering your chances of having another heart attack.
Key documents: Patient Prescribing Information ~ Medication Guide
BRILINTA is a trademark of the AstraZeneca group of companies.
Plavix® is a registered trademark of sanofi-aventis.
News Articles
University of Maryland Medical Center Launches Genetic-Testing Program For Cardiac Stent Patients
BALTIMORE, May 14, 2013 /PRNewswire-USNewswire/ -- Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center now can receive long-term therapy based...
AstraZeneca results - The Economist Intelligence Unit
"Shareholders at AstraZeneca are getting restive. The company has long known that patent expiries, notably for anti-psychotic Seroquel, were going to eat into revenues, but it has so far failed...
Human medicines European Public Assessment Report (EPAR): Possia, ticagrelor, Revision: 2, Withdrawn
Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test
Accumetrics, Inc., developer of the market-leading VerifyNow® System, announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now...
Aggredyne Increases IP Portfolio to Four Patents
Aggredyne, Inc., a Houston-based biomedical diagnostics company that is defining a new standard for platelet function, has added a fourth patent to its intellectual property portf...
AstraZeneca (NYSE: AZN) announced today that a combined panel of experts from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) have...
AstraZeneca (NYSE: AZN) today announced a new program with more than 26,000 national, regional and independent pharmacies to broaden stocking of BRILINTA® (ticagrelor) tab...
AstraZeneca (NYSE: AZN) today announced results from a post-hoc analysis of a sub-group of the PLATO study. This new analysis evaluated outcomes in 9,946 patients with nonâ...
Events
None
Companies
None
Clinical Trials
A 2 by 2 factorial, multicenter, prospective, randomized, open-label, blinded endpoint trial. Patients undergoing primary PCI for STEMI will be eligible. Enrolled patients will be randomly...
Antithrombotic Triple Therapy in Humans
Background:The acute coronary syndrome (ACS) is a complication of coronary artery disease (CAD) and associated with increased mortality. Dual antiplatelet therapy of acetylsalicylic acid (...
The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.
PubMed Articles
Ticagrelor showed significant reductions in myocardial infarctions (MIs) compared to clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. However, there was no explanation as to...
Primary percutaneous coronary intervention (PCI) is the treatment of choice for patients presenting with acute ST-segment elevation myocardial infarction (STEMI). However, if catheterization facilitie...
Primary percutaneous coronary intervention (PPCI) is the reperfusion method of choice in ST elevation myocardial infarction (STEMI). However, STEMI represents a highly pre-thrombotic state with platel...
High platelet reactivity - the challenge of prolonged anticoagulation therapy after ACS.
Despite dual antiplatelet therapy (DAPT), one-year event rates after acute coronary syndrome (ACS) vary from 9-12%. The development of novel oral anticoagulants (NOAC) without a need for monitoring ha...
Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.
This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.
Blood platelets are highly activated in the setting of an acute coronary syndrome (ACS). This fact mandates the need for potent platelet inhibition in ACS patients and especially in patients undergoin...
For several years, clopidogrel plus aspirin has been the dual antiplatelet therapy (DAPT) of choice for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)...
OBJECTIVES: The present trial aims at examining whether antiplatelet regimen modification, guided by assessment of the on-treatment platelet reactivity, might result with clinical benefit in moderate...
The two newer antiplatelet drugs, prasugrel and ticagrelor have both been incorporated in various national guidelines and are both under consideration for approval or have already been approved by var...
Videos
BRILINTA (ticagrelor) Launches "Complete the Course" ...
BRILINTA Broll http://www.businesswire.com/news/home/20120919005238/en/BRILINTA-ticagrelor-Launches-%E2%80%9CComplete-Course%E2%80%9D-%E2%80%94-Creative.
